Those emerging biotechnology companies, or biotechs, that hold the potential to extend human lifespan or even cure cancer are now under dual pressure from slow R&D realization and surging financing costs, and global investors are turning cautious on biotech stocks.
The rapid rise in U.S. Treasury yields has eroded the appeal of these stocks. These companies are often viewed as extremely high-risk investments betting on breakthrough therapies, where the ultimate innovative treatment outcome can be all-or-nothing.
Statistics show that the Nasdaq Biotechnology Index has fallen 3.8% since its August 19 high, while the U.S. 10-year Treasury yield jumped nearly 0.5 percentage points over the same period and at one point touched 5.34%, the highest level since 2002. The index tracks nearly 250 biotech companies and is still up about 25% year-to-date, but the recent pullback indicates that the surge in yields is making stock investors uneasy.
The Surge in Treasury Yields Raises the Hurdle Rate, and Medical Breakthroughs Face a Major Funding Test
Biotech stocks are especially sensitive to rising interest rates, and even more so in terms of risk appetite. These stocks are often seen as lottery-like investments: they may deliver huge returns, or they may end up nearly worthless.
Now, even investing in the safest bonds can generate richer yields, and investor demand for high-risk segments of the stock market is beginning to weaken.
William Soliman, founder and chief investment officer of White Manna Capital, said: "The investment appeal of early-stage biotech companies faces a greater challenge, because investors now have clearly higher-yielding risk-free alternatives."
As shown in the chart above, as the 10-year Treasury yield climbed across the board, biotech stock prices generally fell sharply, with the biotech index down nearly 4% from its August 19 high. Note: The biotech index is standardized using August 19 as the base date.
Driven by soaring energy prices and companies borrowing heavily for AI businesses, U.S. Treasury yields have risen rapidly this year. The 10-year Treasury yield quickly broke above 5%, highlighting investor concerns that inflation remains stubborn even as the Federal Reserve pledges to suppress price pressures.
This creates a more complicated environment for biotech companies that were already short of funds. Data compiled by Bloomberg shows that among constituents of the Nasdaq Biotechnology Index, fewer than a quarter have been profitable over the past year, and about half do not have enough existing cash to cover six months of daily expenses.
Soliman added that in a higher-rate environment, biotech investors will demand higher returns to compensate for the clinical, regulatory and financing risks involved in a company that may still need years to generate revenue.
The chart above shows the "number of months biotech companies' cash can support," compiled by institutions. About half of the companies in the biotech index do not even have enough cash to last about six months. Note: The data was compiled on October 21 based on constituent companies of the Nasdaq Biotechnology Index.
Still, some institutional investors who have long been bullish on the biotech sector, such as Gabelli portfolio manager Elena Meng, remain firmly optimistic about biotech over the long term. She said: "We have always attached great importance to valuation when investing in biotech, so changes in interest rates do not fundamentally change our investment approach."
The sector has also had bright spots this year. Positive trial data released by Moderna and Merck & Co. raised market expectations for treating the deadliest skin cancer, driving Moderna shares up more than 700% year-to-date in 2026 after four consecutive full years of declines.
An oral drug from Revolution Medicines that can extend the lives of patients with advanced pancreatic cancer was approved in the United States, driving its shares up more than 140% this year.
Meng said that while rising interest rates affect biotech companies' cost of capital, cash runway and financing risk, Gabelli's investment evaluation process has already taken these factors into account.
From Cancer Breakthroughs to Halting Research and Seeking a Sale: What Determines Destiny Is More Than the Science Progress Bar
Analysts at RBC Capital Markets are also bullish on biotech stocks, expecting that if the AI computing power trade theme cools across the board, the sector will benefit from accelerating capital rotation out of tech stocks.
However, Mike Perrone, a healthcare industry expert at Baird, said that because the sector's performance is closely tied to clinical trial results, negative news from several large companies would weaken investor enthusiasm for these stocks.
Signs of stress have already appeared. Caribou Biosciences, which focuses on genome editing, said earlier this month that it plans to stop two therapeutic programs and explore strategic options, including a potential merger or acquisition. The company also plans layoffs and cost cuts, and its shares have fallen more than 60% this year.
Caribou CEO Rachel Haurwitz said many investors "have completely stopped prioritizing new investments in this field, because a large number of deal opportunities are emerging in other exciting areas."
Perrone said the current interest rate environment will make it difficult for biotech stocks to attract investors who are not focused on the sector but allocate capital across industries.
Concerns about rising interest rates have already pushed Wall Street investors to withdraw from equity funds and move into safe-haven assets. Although major U.S. stock indexes hit new highs earlier this month, some argue that this resilience is concentrated in only a few dozen stocks.
Perrone said: "This will hinder generalist investors from returning, because they place more emphasis on macro factors when judging when to rotate into the biotech sector. A clearly negative factor such as rising interest rates will make them even more hesitant."
The term "all-or-nothing" usually describes valuations that depend heavily on the success or failure of a few key programs, and it is not a common feature of all biotech companies.
Leading "all-or-nothing" biotechs are usually concentrated in innovative oncology treatments. For example, Moderna and Merck & Co. are developing individualized neoantigen therapy, using messenger RNA (mRNA) to help the immune system recognize tumors, and the combination therapy has achieved positive Phase III results. Revolution Medicines' RAS inhibitor belongs to small-molecule targeted therapy, and its pancreatic cancer drug has been approved in the United States. The two respectively reflect value revaluation brought by clinical validation and commercialization access.
Undoubtedly, for these companies, persistently high interest rates will increase the risk of financing failure, halted research and asset sales. A cash runway of less than six months means financing urgency, but that does not equal certain bankruptcy within six months.
Companies can continue operating through cost cuts, licensing, additional share issuance or M&A, but existing shareholders may bear significant dilution.
Caribou announced on October 6 that it would stop development of two allogeneic CAR-T cell therapies, cut jobs and seek strategic transactions, explicitly citing financing difficulties, and has not yet declared bankruptcy.
Between major scientific potential and shareholder returns lies the question of whether a company can raise funds to complete R&D.
Comments